Annexon's vonaprunment selected for EMA's PDC pilot program

Summary

Annexon has announced that its drug vonaprument (formerly anx007) has been selected by the EMA for participation in the PDC pilot program. This first-in-kind treatment aims to block C1q in the eye and has received prime designation in Europe and fast track designation from the FDA. The PDC pilot, launched in July 2025, will assist in regulatory interactions and support the development of vonaprument, which is currently in a phase III trial for treating advanced dry age-related macular degeneration. Topline data is expected in late 2026.Pharmaceutical Business Review

Impact Analysis

This event represents a significant product milestone and regulatory advancement for Annexon. The selection by the EMA for the PDC pilot program could facilitate smoother regulatory processes and accelerate the drug’s path to market. First-order effects include improved growth prospects as vonaprument gains recognition and potentially faster approval. The drug’s participation in the pilot, along with its designations, positions it as a promising treatment for age-related macular degeneration, increasing its market attractiveness. Risks involve the successful completion of the Phase III trial and subsequent approval processes. Second-order effects might see increased interest and pressure from competitors in the neurology and ophthalmology sectors. Investment opportunities could involve strategic positioning in Annexon’s stock, considering the potential market approval and subsequent revenue streams.Pharmaceutical Business Review+ 2